Delving into the Latest Updates on Ad5-S-nb2 with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target

SARS-CoV-2 S protein

Action

inhibitors

Mechanism

SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Guangzhou Enbao Biomedical Technology Co., Ltd.

Active Organization

Guangzhou Enbao Biomedical Technology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Liu, Xinglong ; Hu, Peiyu ; Zhong, Nanshan ; Yuan, Zhiming ; Niu, Xuefeng ; Li, Chufang ; Liu, Xiaolin ; Yang, Chenchen ; Li, Pingchao ; Liu, Bo ; Zhao, Jincun ; Guan, Suhua ; Zhang, Fan ; Jiang, Rendi ; Ke, Changwen ; Wang, Qian ; Chen, Xinwen ; Xu, Yongcun ; Luo, Jia ; Liu, Yichu ; Chen, Ling ; Pan, Weiqi ; Zhou, Yiwu ; Gu, Yingying ; Xu, Tao ; Sun, Jing ; Zheng, Xuehua ; Feng, Ying ; Wu, Jia ; Shan, Chao ; Feng, Liqiang

AbstractThe rapid spread of coronavirus SARS-CoV-2 greatly threatens global public health but no prophylactic vaccine is available. Here, we report the generation of a replication-incompetent recombinant serotype 5 adenovirus, Ad5-S-nb2, carrying a codon-optimized gene encoding Spike protein (S). In mice and rhesus macaques, intramuscular injection with Ad5-S-nb2 elicits systemic S-specific antibody and cell-mediated immune (CMI) responses. Intranasal inoculation elicits both systemic and pulmonary antibody responses but weaker CMI response. At 30 days after a single vaccination with Ad5-S-nb2 either intramuscularly or intranasally, macaques are protected against SARS-CoV-2 challenge. A subsequent challenge reveals that macaques vaccinated with a 10-fold lower vaccine dosage (1 × 1010 viral particles) are also protected, demonstrating the effectiveness of Ad5-S-nb2 and the possibility of offering more vaccine dosages within a shorter timeframe. Thus, Ad5-S-nb2 is a promising candidate vaccine and warrants further clinical evaluation.

100 Deals associated with Ad5-S-nb2

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Preclinical	China	Guangzhou Enbao Biomedical Technology Co., Ltd.	21 Aug 2020
Coronavirus Infections	Discovery	China	Guangzhou Enbao Biomedical Technology Co., Ltd.	21 Aug 2020